Aytu Bioscience (NASDAQ:AYTU) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, November 7th. Analysts expect Aytu Bioscience to post earnings of ($1.45) per share for the quarter.
Shares of NASDAQ AYTU opened at $1.11 on Tuesday. Aytu Bioscience has a 1-year low of $1.01 and a 1-year high of $123.00. The stock has a market capitalization of $2.05 million, a price-to-earnings ratio of -0.04 and a beta of 6.25.
Separately, Northland Securities assumed coverage on shares of Aytu Bioscience in a research note on Monday, October 22nd. They issued an “outperform” rating and a $10.00 target price for the company.
WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/11/06/aytu-bioscience-aytu-scheduled-to-post-earnings-on-wednesday.html.
Aytu Bioscience Company Profile
Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.
Featured Story: The risks of owning bonds
Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.